Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences
Key Highlights
- ➤Three EP-104GI abstracts accepted for ACG and UEG medical conferences
- ➤EP-104GI dysphagia improvements persisted up to 52 weeks after single administration
- ➤RESOLVE Phase 2b trial recruiting 120mg and 160mg doses
- ➤RESOLVE Phase 2b interim data expected in December 2026
- ➤Additional Phase 1b/2a RESOLVE data planned in coming months
VANCOUVER, British Columbia, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today is pleased to announce that three abstracts related to Company’s ongoing Phase 1b/2 RESOLVE trial of EP-104GI for the treatment of eosinophilic esophagitis ("EoE") have been accepted and will be presented at: (i) the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting & Postgraduate Course, being held October 9-14, 2026 in Nashville, Tennessee, and (ii) the United European Gastroenterology (UEG) Week 2026, being held October 17-20, 2026 in Barcelona, Spain.
ACG 2026 Annual Scientific Meeting & Postgraduate Course Nashville, Tennessee; October 9-14, 2026
Get started
Create a free account to read the full story.